British Study Links EZH2 Enzyme to Poorer Myeloma Patient Survival
Multiple myeloma patients with high levels of the EZH2 enzyme have shorter survival times, regardless of the treatment they receive, a British study reports. The…
Alice Melão, —
Articles by Alice Melão
Alice Melão, —
Articles by Alice Melão
Cellectar’s CLR 131 Shows Positive Phase 1 Trial Results for Heavily Treated Myeloma Patients
All three relapsed or refractory multiple myeloma patients in the final group of Cellectar Biosciences‘ Phase 1 trial of CLR 131 benefited from treatment, researchers said.
Acupuncture Helps to Manage Effects of HSCT and Chemo in Myeloma Patients, Study Says
Acupuncture can help ease the nausea and drowsiness that follows an autologous hematopoietic stem cell transplant in multiple myeloma patients, a new study suggests. These symptoms…
Japanese Regulator Approves Darzalex Combo for Relapsed or Refractory Multiple Myeloma
The Japanese Ministry of Health, Labor, and Welfare has approved Darzalex (daratumumab) in combination with either Revlimid (lenalidomide) and dexamethasone, or Velcade (bortezomib)…
Unum’s T-Cell Therapy Enters Phase 1 Trial for Relapsed or Refractory Multiple Myeloma
The U.S. Food and Drug Administration (FDA) recently approved an investigational new drug (IND) application filed by Unum Therapeutics for its ACTR087 T-cell therapy…
Long-term Data Confirms Kyprolis Survival Benefit in Relapsed Myeloma Patients
New long-term data from the Phase 3 ENDEAVOR trial has shown that relapsed multiple myeloma patients treated with Kyprolis (carfilzomib) plus dexamethasone survive a median of…
Imbruvica Becomes 1st FDA-Approved Therapy for Graft-Versus-Host-Disease in Adults
The U.S. Food and Drug Administration (FDA) has approved Imbruvica (ibrutinib) for the treatment of chronic graft-versus-host-disease (cGVHD), a common complication of stem cell or bone…
STRO-001 Eliminates or Slows Growth of Myeloma and Lymphoma in Mice, Studies Show
Sutro Biopharma‘s STRO-001 eliminates or significantly slows the growth of non-Hodgkin lymphoma and multiple myeloma tumors, studies in mice indicate. Sutro expects the results to support…
Adding Darzalex to Standard Therapies in Multiple Myeloma Patients Continues to Show Improved Results
Adding Darzalex (daratumumab) to standard care therapies continues to show improved effectiveness in treating relapsed or refractory multiple myeloma, with no related toxicity, according to updated…
One World Cannabis to Test Mice in Pursuit of Therapies Targeting Multiple Myeloma Cancer Cells
Israel’s One World Cannabis (OWC) says it’s moving forward to mouse models to test its unique formula of cannabinoid-based therapies targeting cancer cells. This decision followed promising results…
